These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 16919960

  • 1. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L, Ikeda K, Kato A, Adachi I, Godin G, Compain P, Martin O, Asano N.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7736-44. PubMed ID: 16919960
    [Abstract] [Full Text] [Related]

  • 2. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
    Alfonso P, Pampín S, Estrada J, Rodríguez-Rey JC, Giraldo P, Sancho J, Pocoví M.
    Blood Cells Mol Dis; 2005 Dec 01; 35(2):268-76. PubMed ID: 16039881
    [Abstract] [Full Text] [Related]

  • 3. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z, Higaki K, Aguilar-Moncayo M, Ninomiya H, Ohno K, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Suzuki Y.
    Chembiochem; 2009 Nov 23; 10(17):2780-92. PubMed ID: 19830760
    [Abstract] [Full Text] [Related]

  • 4. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.
    Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW.
    Proc Natl Acad Sci U S A; 2002 Nov 26; 99(24):15428-33. PubMed ID: 12434014
    [Abstract] [Full Text] [Related]

  • 5. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G, Duque J, Egido-Gabás M, Casas J, Lluch M, Chabás A, Grinberg D, Vilageliu L.
    Blood Cells Mol Dis; 2009 Nov 26; 42(2):159-66. PubMed ID: 19167250
    [Abstract] [Full Text] [Related]

  • 6. Amphiphilic 1-deoxynojirimycin derivatives through click strategies for chemical chaperoning in N370S Gaucher cells.
    Diot JD, Garcia Moreno I, Twigg G, Ortiz Mellet C, Haupt K, Butters TD, Kovensky J, Gouin SG.
    J Org Chem; 2011 Oct 07; 76(19):7757-68. PubMed ID: 21830816
    [Abstract] [Full Text] [Related]

  • 7. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
    Thirumal Kumar D, Iyer S, Christy JP, Siva R, Tayubi IA, George Priya Doss C, Zayed H.
    Adv Protein Chem Struct Biol; 2019 Oct 07; 114():315-339. PubMed ID: 30635084
    [Abstract] [Full Text] [Related]

  • 8. Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.
    Wang GN, Twigg G, Butters TD, Zhang S, Zhang L, Zhang LH, Ye XS.
    Org Biomol Chem; 2012 Apr 21; 10(15):2923-7. PubMed ID: 22286559
    [Abstract] [Full Text] [Related]

  • 9. A Fluorescent sp2-iminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies.
    Luan Z, Higaki K, Aguilar-Moncayo M, Li L, Ninomiya H, Nanba E, Ohno K, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Suzuki Y.
    Chembiochem; 2010 Nov 22; 11(17):2453-64. PubMed ID: 21064079
    [Abstract] [Full Text] [Related]

  • 10. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ.
    FEBS J; 2006 Sep 22; 273(17):4082-92. PubMed ID: 16934036
    [Abstract] [Full Text] [Related]

  • 11. Biological properties of D- and L-1-deoxyazasugars.
    Kato A, Kato N, Kano E, Adachi I, Ikeda K, Yu L, Okamoto T, Banba Y, Ouchi H, Takahata H, Asano N.
    J Med Chem; 2005 Mar 24; 48(6):2036-44. PubMed ID: 15771446
    [Abstract] [Full Text] [Related]

  • 12. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Sawkar AR, Adamski-Werner SL, Cheng WC, Wong CH, Beutler E, Zimmer KP, Kelly JW.
    Chem Biol; 2005 Nov 24; 12(11):1235-44. PubMed ID: 16298303
    [Abstract] [Full Text] [Related]

  • 13. In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
    Kuriyama C, Kamiyama O, Ikeda K, Sanae F, Kato A, Adachi I, Imahori T, Takahata H, Okamoto T, Asano N.
    Bioorg Med Chem; 2008 Aug 01; 16(15):7330-6. PubMed ID: 18595718
    [Abstract] [Full Text] [Related]

  • 14. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
    Cheng WC, Weng CY, Yun WY, Chang SY, Lin YC, Tsai FJ, Huang FY, Chen YR.
    Bioorg Med Chem; 2013 Sep 01; 21(17):5021-8. PubMed ID: 23880081
    [Abstract] [Full Text] [Related]

  • 15. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
    Wang GN, Reinkensmeier G, Zhang SW, Zhou J, Zhang LR, Zhang LH, Butters TD, Ye XS.
    J Med Chem; 2009 May 28; 52(10):3146-9. PubMed ID: 19397268
    [Abstract] [Full Text] [Related]

  • 16. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.
    Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL.
    J Biol Chem; 2007 Sep 28; 282(39):29052-29058. PubMed ID: 17666401
    [Abstract] [Full Text] [Related]

  • 17. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR, Schmitz M, Zimmer KP, Reczek D, Edmunds T, Balch WE, Kelly JW.
    ACS Chem Biol; 2006 May 23; 1(4):235-51. PubMed ID: 17163678
    [Abstract] [Full Text] [Related]

  • 18. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.
    Joosten A, Decroocq C, de Sousa J, Schneider JP, Etamé E, Bodlenner A, Butters TD, Compain P.
    Chembiochem; 2014 Jan 24; 15(2):309-19. PubMed ID: 24375964
    [Abstract] [Full Text] [Related]

  • 19. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.
    Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ.
    Mol Genet Metab; 2007 Jan 24; 90(1):49-57. PubMed ID: 17095274
    [Abstract] [Full Text] [Related]

  • 20. Probing the Inhibitor versus Chaperone Properties of sp²-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease.
    Mena-Barragán T, García-Moreno MI, Sevšek A, Okazaki T, Nanba E, Higaki K, Martin NI, Pieters RJ, Fernández JMG, Mellet CO.
    Molecules; 2018 Apr 17; 23(4):. PubMed ID: 29673163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.